Literature DB >> 15757811

General management.

Mindie H Nguyen1, Emmet B Keeffe.   

Abstract

Hepatocellular carcinoma is one of the most common malignancies worldwide. The general management of hepatocellular carcinoma begins with an accurate diagnosis. With advances in imaging studies, noninvasive diagnosis has become an accepted standard of care for hepatocellular carcinoma, though pathologic examination is still required in selected cases. Following diagnosis, accurate staging is the next most important step in selecting the most appropriate treatment modality. Patients with localised tumor and compensated liver disease should be considered for partial hepatectomy, and patients with poor hepatic function but early tumor stage are candidates for liver transplantation. Patients who do not qualify for either of these curative treatments may be evaluated for palliative therapy, of which transarterial chemoembolisation is most widely used. This review will discuss the role of biopsy, the pros and cons of noninvasive and pathologic tissue diagnosis as well as the general approach to choose the most appropriate treatment for patients with hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757811     DOI: 10.1016/j.bpg.2004.11.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  2 in total

1.  Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting.

Authors:  Carrie R Wong; Ruel T Garcia; Huy N Trinh; Khoa D Lam; Nghi B Ha; Huy A Nguyen; Khanh K Nguyen; Brian S Levitt; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2009-10-30       Impact factor: 3.199

2.  Ambovex(®) as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial.

Authors:  Hosny Salama; Hassan Ahmad; Ismail Elchagea; Abdel Rahman Zekri; Eman Medhat; Abeer Bahnassy; Michael Lange; Mohammed Rabbat; Andrew N de la Torre; Pravin Punamiya
Journal:  J Hepatocell Carcinoma       Date:  2015-06-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.